Dr Reddy's Laboratories Receivables 2010-2024 | RDY

Dr Reddy's Laboratories receivables from 2010 to 2024. Receivables can be defined as the total amount of collectibles for a company
  • Dr Reddy's Laboratories receivables for the quarter ending September 30, 2024 were $1.008B, a 20.14% increase year-over-year.
  • Dr Reddy's Laboratories receivables for 2024 were $0.963B, a 9.18% increase from 2023.
  • Dr Reddy's Laboratories receivables for 2023 were $0.882B, a 0.23% increase from 2022.
  • Dr Reddy's Laboratories receivables for 2022 were $0.88B, a 29.6% increase from 2021.
Dr Reddy's Laboratories Annual Receivables
(Millions of US $)
2024 $963
2023 $882
2022 $880
2021 $679
2020 $667
2019 $576
2018 $624
2017 $587
2016 $623
2015 $654
2014 $551
2013 $586
2012 $498
2011 $395
2010 $266
2009 $
Dr Reddy's Laboratories Quarterly Receivables
(Millions of US $)
2024-09-30 $1,008
2024-06-30 $973
2024-03-31 $963
2023-12-31 $943
2023-09-30 $839
2023-06-30 $939
2023-03-31 $882
2022-12-31 $907
2022-09-30 $946
2022-06-30 $927
2022-03-31 $880
2021-12-31 $839
2021-09-30 $926
2021-06-30 $821
2021-03-31 $679
2020-12-31 $728
2020-09-30 $681
2020-06-30 $617
2020-03-31 $667
2019-12-31 $622
2019-09-30 $576
2019-06-30 $549
2019-03-31 $576
2018-12-31 $535
2018-09-30 $636
2018-06-30 $700
2018-03-31 $624
2017-12-31 $665
2017-09-30 $646
2017-06-30 $637
2017-03-31 $587
2016-12-31 $605
2016-09-30 $555
2016-06-30 $526
2016-03-31 $623
2015-12-31 $633
2015-09-30 $654
2015-06-30 $661
2015-03-31 $654
2014-12-31 $638
2014-09-30 $609
2014-06-30 $601
2014-03-31 $551
2013-12-31 $562
2013-09-30 $532
2013-06-30 $490
2013-03-31 $586
2012-12-31 $497
2012-09-30 $496
2012-06-30 $449
2012-03-31 $498
2011-12-31 $498
2011-09-30 $419
2011-06-30 $384
2011-03-31 $395
2010-12-31 $314
2010-09-30 $288
2010-06-30 $275
2010-03-31 $266
2009-12-31 $250
2009-09-30 $272
2009-06-30 $280
2009-03-31 $287
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $11.677B $3.350B
Dr. Reddy's Laboratories Ltd. is an integrated global pharmaceutical company engaged in providing affordable and innovative medicines since 1984. The company markets its products in countries like the U.S., the UK, Germany, India, Russia, Venezuela, Romania and South Africa. Dr. Reddy's operates through three segments: Global Generics comprising unbranded prescription drugs along with over-the-counter drugs. It includes the operations of the company's biologics business. Pharmaceutical Services & Active Ingredients (PSAI) comprising active pharmaceutical ingredients (API) and custom pharmaceutical services. Proprietary Products and Others involving the new chemical entities, the differentiated formulations business and a dermatology specialty business. The company has a strategic partnership with Glaxo to market selected products across emerging markets outside India.
Stock Name Country Market Cap PE Ratio
Teva Pharmaceutical Industries (TEVA) Israel $19.350B 6.35
BridgeBio Pharma (BBIO) United States $4.392B 0.00
Bausch Health Cos (BHC) Canada $3.009B 2.18
Amphastar Pharmaceuticals (AMPH) United States $2.142B 12.88
Supernus Pharmaceuticals (SUPN) United States $1.978B 26.93
Taysha Gene Therapies (TSHA) United States $0.447B 31.14
Personalis (PSNL) United States $0.239B 0.00
Assembly Biosciences (ASMB) United States $0.094B 0.00
Sol-Gel Technologies (SLGL) Israel $0.013B 0.00
Evoke Pharma (EVOK) United States $0.007B 0.00
Teligent (TLGT) United States $0.000B 0.00